Anika Therapeutics (ANIK) Current Assets (2010 - 2026)

Anika Therapeutics (ANIK) has reported Current Assets for 17 consecutive years, with $99.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Assets changed 0.13% year-over-year to $99.2 million in Q2 2026; TTM through Jun 2026 was $99.2 million, a 0.13% change from a year earlier, with the FY2025 full-year figure at $103.4 million, down 9.06% from the prior year.
• Current Assets was $99.2 million for Q2 2026 at Anika Therapeutics, up from $93.6 million in the prior quarter.
• Over five years, Current Assets peaked at $169.5 million in Q4 2022 and troughed at $93.6 million in Q1 2026.
• A 5-year average of $137.0 million and a median of $153.6 million in 2023 frame the typical range for Current Assets.
• Across the five-year window, Current Assets climbed 1.84% in 2024 and tumbled 35.92% in 2025, its largest moves.
• Over 5 years, Current Assets stood at $169.5 million in 2022, then declined by 3.68% to $163.3 million in 2023, then sank by 30.41% to $113.7 million in 2024, then slipped by 9.06% to $103.4 million in 2025, then decreased by 4.03% to $99.2 million in 2026.
• The last three Current Assets figures came in at $99.2 million (Q2 2026), $93.6 million (Q1 2026), and $103.4 million (Q4 2025), per Business Quant data.